Ceftobiprole medocaril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Ceftobiprole medocaril is a cephalosporin indicated in the treatment of pneumonia.

Generic Name
Ceftobiprole medocaril
DrugBank Accession Number
DB14733
Background

Ceftobiprole medocaril is a ceftobiprole prodrug.

Type
Small Molecule
Groups
Experimental, Investigational
Structure
Thumb
Weight
Average: 690.66
Monoisotopic: 690.116246037
Chemical Formula
C26H26N8O11S2
Synonyms
  • Ceftobiprole medocaril
  • Ceftobiprole medocaril free acid

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of bleeding can be increased when Ceftobiprole medocaril is combined with Acenocoumarol.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ceftobiprole medocaril.
DicoumarolThe risk or severity of bleeding can be increased when Ceftobiprole medocaril is combined with Dicoumarol.
EstetrolThe therapeutic efficacy of Estetrol can be decreased when used in combination with Ceftobiprole medocaril.
FluindioneThe risk or severity of bleeding can be increased when Ceftobiprole medocaril is combined with Fluindione.
PhenindioneThe risk or severity of bleeding can be increased when Ceftobiprole medocaril is combined with Phenindione.
PhenprocoumonThe risk or severity of bleeding can be increased when Ceftobiprole medocaril is combined with Phenprocoumon.
Typhoid vaccineThe therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ceftobiprole medocaril.
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ceftobiprole medocaril.
WarfarinThe risk or severity of bleeding can be increased when Ceftobiprole medocaril is combined with Warfarin.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Ceftobiprole medocaril sodiumN99027V28J252188-71-9MFAWUGGPPMTWPU-LCJFHXTKSA-M

Categories

ATC Codes
J01DI01 — Ceftobiprole medocaril
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
YXV28V1B07
CAS number
376653-43-9
InChI Key
HFTSMHTWUFCYMJ-YIOMYIDASA-N
InChI
InChI=1S/C26H26N8O11S2/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31)/b11-6+,30-15-/t13-,16-,22-/m1/s1
IUPAC Name
(6R,7R)-7-[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(N-hydroxyimino)acetamido]-3-{[(3E,3'R)-1'-{[(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methoxy]carbonyl}-2-oxo-[1,3'-bipyrrolidin]-3-ylidene]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@@]1(NC(=O)C(=N/O)\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\C=C1/CCN(C1=O)[C@]1([H])CCN(C1)C(=O)OCC1=C(C)OC(=O)O1

References

General References
  1. AIFA Product Information: MABELIO (ceftobiprole medocaril) injection [Link]
ChemSpider
28475342
ChEBI
135968
Wikipedia
Ceftobiprole

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAcute Bacterial Skin and Skin Structure Infection (ABSSSI)1
3CompletedTreatmentCommunity Acquired Pneumonia (CAP) / Hospital-acquired Pneumonia (HAP) / Nosocomial Pneumonia1
3CompletedTreatmentPneumonia1
3CompletedTreatmentSkin Diseases, Bacterial / Skin Diseases, Infectious / Staphylococcal Skin Infections2
3RecruitingTreatmentStaphylococcus Aureus Bacteraemia1
3TerminatedTreatmentFever / Gram Positive Bacterial Infections / Neutropenia / Pseudomonas Infections1
2CompletedTreatmentInflamed Meninges / Suspected Meningitis / Ventriculitis1
2WithdrawnTreatmentBacteremia1
1TerminatedTreatmentBacterial Infections1
Not AvailableRecruitingNot AvailableHepatic Insufficiency / Immunosuppression / Impaired Renal Function1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionParenteral
PowderIntravenous666.6 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.131 mg/mLALOGPS
logP0.16ALOGPS
logP-0.97ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)3.19ChemAxon
pKa (Strongest Basic)0.43ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area256.48 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity163.59 m3·mol-1ChemAxon
Polarizability64.88 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on January 27, 2019 21:57 / Updated on May 14, 2021 01:07